US Code
Part A— Drugs and Devices
§ 356f. Hospital repackaging of drugs in shortage

(a) DefinitionsIn this section:(1) DrugThe term “drug” excludes any controlled substance (as such term is defined in section 802 of this title).
(2) Health systemThe term “health system” means a collection of hospitals that are owned and operated by the same entity and that share access to databases with drug order information for their patients.
(3) RepackageFor the purposes of this section only, the term “repackage”, with respect to a drug, means to divide the volume of a drug into smaller amounts in order to—(A) extend the supply of a drug in response to the placement of the drug on a drug shortage list under section 356e of this title; and
(B) facilitate access to the drug by hospitals within the same health system.
(b) Exclusion from registrationNotwithstanding any other provision of this chapter, a hospital shall not be considered an establishment for which registration is required under section 360 of this title solely because it repackages a drug and transfers it to another hospital within the same health system in accordance with the conditions in subsection (c)—(1) during any period in which the drug is listed on the drug shortage list under section 356e of this title; or
(2) during the 60-day period following any period described in paragraph (1).
(c) ConditionsSubsection (b) shall only apply to a hospital, with respect to the repackaging of a drug for transfer to another hospital within the same health system, if the following conditions are met:(1) Drug for intrasystem use onlyIn no case may a drug that has been repackaged in accordance with this section be sold or otherwise distributed by the health system or a hospital within the system to an entity or individual that is not a hospital within such health system.
(2) Compliance with State rulesRepackaging of a drug under this section shall be done in compliance with applicable State requirements of each State in which the drug is repackaged and received.
(d) TerminationThis section shall not apply on or after the date on which the Secretary issues final guidance that clarifies the policy of the Food and Drug Administration regarding hospital pharmacies repackaging and safely transferring repackaged drugs to other hospitals within the same health system during a drug shortage.

Structure US Code

US Code

Title 21— FOOD AND DRUGS

CHAPTER 9— FEDERAL FOOD, DRUG, AND COSMETIC ACT

SUBCHAPTER V— DRUGS AND DEVICES

Part A— Drugs and Devices

§ 351. Adulterated drugs and devices

§ 352. Misbranded drugs and devices

§ 353. Exemptions and consideration for certain drugs, devices, and biological products

§ 353a. Pharmacy compounding

§ 353a–1. Enhanced communication

§ 353b. Outsourcing facilities

§ 353c. Prereview of television advertisements

§ 353d. Process to update labeling for certain generic drugs

§ 354. Veterinary feed directive drugs

§ 355. New drugs

§ 355–1. Risk evaluation and mitigation strategies

§ 355–2. Actions for delays of generic drugs and biosimilar biological products

§ 355a. Pediatric studies of drugs

§ 355b. Adverse-event reporting

§ 355c. Research into pediatric uses for drugs and biological products

§ 355c–1. Report

§ 355d. Internal committee for review of pediatric plans, assessments, deferrals, deferral extensions, and waivers

§ 355e. Pharmaceutical security

§ 355f. Extension of exclusivity period for new qualified infectious disease products

§ 355g. Utilizing real world evidence

§ 355h. Regulation of certain nonprescription drugs that are marketed without an approved drug application

§ 356. Expedited approval of drugs for serious or life-threatening diseases or conditions

§ 356–1. Accelerated approval of priority countermeasures

§ 356–2. Accelerated approval Council

§ 356a. Manufacturing changes

§ 356b. Reports of postmarketing studies

§ 356c. Discontinuance or interruption in the production of life-saving drugs

§ 356c–1. Annual reporting on drug shortages

§ 356d. Coordination; task force and strategic plan

§ 356e. Drug shortage list

§ 356f. Hospital repackaging of drugs in shortage

§ 356g. Standards for regenerative medicine and regenerative advanced therapies

§ 356h. Competitive generic therapies

§ 356i. Prompt reports of marketing status

§ 356j. Discontinuance or interruption in the production of medical devices

§ 356k. Platform technologies

§ 356l. Advanced manufacturing technologies designation program

§ 357. Qualification of drug development tools

§ 358. Authority to designate official names

§ 359. Nonapplicability of subchapter to cosmetics

§ 360. Registration of producers of drugs or devices

§ 360a. Clinical trial guidance for antibiotic drugs

§ 360a–1. Clinical trials

§ 360a–2. Susceptibility test interpretive criteria for microorganisms

§ 360b. New animal drugs

§ 360b–1. Priority zoonotic animal drugs

§ 360c. Classification of devices intended for human use

§ 360c–1. Reporting

§ 360d. Performance standards

§ 360e. Premarket approval

§ 360e–1. Pediatric uses of devices

§ 360e–3. Breakthrough devices

§ 360e–4. Predetermined change control plans for devices

§ 360f. Banned devices

§ 360g. Judicial review

§ 360g–1. Agency documentation and review of significant decisions regarding devices

§ 360g–2. Third party data transparency

§ 360h. Notification and other remedies

§ 360h–1. Program to improve the device recall system

§ 360i. Records and reports on devices

§ 360j. General provisions respecting control of devices intended for human use

§ 360k. State and local requirements respecting devices

§ 360l. Postmarket surveillance

§ 360m. Accredited persons

§ 360n. Priority review to encourage treatments for tropical diseases

§ 360n–1. Priority review for qualified infectious disease products

§ 360n–2. Ensuring cybersecurity of devices